A monoclonal antibody to which a cell-killing drug has been attached. The antibody combines preferentially with receptors on undesired cells (e.g., cancer cells) and delivers its lethal drug to those cells but not to healthy cells and tissues. To increase their effectiveness and decrease immune responses to these cells, genes for antigen binding sites from human antibodies have been added, creating “humanized” monoclonal antibodies.